Price: $499.93, Change: $+0.31, Percent Change: +0.06%
Related Articles
Wire
Agios Gets EU Approval for Pyrukynd in Thalassemia
Agios Pharmaceuticals (AGIO) said Friday the European Commission granted marketing authorization for Pyrukynd to treat adults with anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia.The oral therapy received orphan medicinal product designation in the European Union.The approval was based on results from the two phase 3 clinical trials evaluating the medicine in adults with thalassemia, Agios said.The company added that its partner, Avanzanite Bioscience, will continue to commercialize and distribute Pyrukynd across Europe.Price: $28.58, Change: $-0.21, Percent Change: -0.73%
$AGIO
Wire
Baird Adjusts Agilent Technologies Price Target to $156 From $155, Maintains Outperform Rating
Agilent Technologies (A) has an average rating of overweight and mean price target of $161.21, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $115.35, Change: $+0.56, Percent Change: +0.49%
$A
Wire
Tigress Financial Cuts Monday.com Price Target to $165 From $310, Maintains Buy Rating
Monday.com (MNDY) has an average rating of overweight and mean price target of $105.65, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $78.88, Change: $+2.62, Percent Change: +3.44%
$MNDY